J. Kimura

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis

H. Nakagawa, A. Taniguchi, Yoshiya Tanaka, 2019, Advances in Therapy.

Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

Y. Ando, H. Tanii, S. Oizumi, 2012, Investigational New Drugs.

Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan

Shigeto Kobayashi, Junko Kimura, Tomoko Kashiwagi, 2018, Modern rheumatology.

Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

H. Yamanaka, N. Miyasaka, Yoshiya Tanaka, 2017, Arthritis Research & Therapy.

Patient preference for biologic treatments of psoriasis in Japan

Y. Tada, K. Ishii, I. Kawaguchi, 2019, The Journal of dermatology.

Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan

H. Yamanaka, T. Mimori, Yoshiya Tanaka, 2018, Modern rheumatology.

Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan

H. Yamanaka, T. Mimori, Yoshiya Tanaka, 2020, Modern rheumatology.